JAK inhibitors Archives - Drugs in Context

JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review

Beatriz Henriques dos Santos, João Domingues, Marco Sousa, Tiago Torres

Article Type

Review

Published

22 Oct 2025

This narrative review evaluates current evidence on the efficacy and safety of JAK inhibitors in the treatment of palmoplantar pustulosis.

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature

Giuseppe Lopalco, Arianna D’Antonio, Maria Sole Chimenti, Florenzo Iannone

Article Type

Case Series & Review

Published

12 May 2025

Four case studies described here illustrate the effectiveness of upadacitinib in a range of real-world patients with axial spondyloarthritis.

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date

Sofia Faria, Egídio Freitas, Tiago Torres

Article Type

Review

Published

25 Sep 2023

In this review, the authors summarize the efficacy, safety and mechanism of action of baricitinib for the treatment of alopecia areata and explore the pathophysiological pathways leading to this disorder.

Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients

Tiago Torres, Margarida Gonçalo, Maria João Paiva Lopes, Cristina Claro, Leonor Ramos, Manuela Selores, Pedro Mendes Bastos, Joana Rocha, Rodrigo Carvalho, Alberto Mota, Paulo Filipe on Behalf of the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology

Article Type

Recommendation

Published

30 Dec 2021

This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-tosevere atopic dermatitis with biologic agents and Janus kinase inhibitors based on the available evidence.

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Novin Nezamololama, BSc, MSc, Keira Fieldhouse, BSc, Kristy Metzger, BSc, Melinda Gooderham, MD, MSc, FRCPC

Article Type

Review

Published

16 Nov 2020

This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of atopic dermatitis.